Feverfew
Research reviewed: Up until 03/2026
Feverfew (Tanacetum parthenium) is a dietary supplement with 5 published peer-reviewed studies involving 899 participants, researched for Migraine Prevention, Anti-Inflammatory & Pain Relief.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Migraine Prevention
ModerateAnti-Inflammatory & Pain Relief
WeakResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Migraine Prevention
To evaluate the efficacy of Tanacetum parthenium (feverfew) in migraine relief
Study Type
Systematic review and meta-analysis
Purpose
To evaluate the efficacy of Tanacetum parthenium (feverfew) in migraine relief
Dose
Various feverfew preparations (50-150 mg/day typical)
Participants
Meta-analysis of 9 double-masked, placebo-controlled RCTs (899 participants)
Duration
Various (8-16 weeks typical)
Results
Feverfew significantly reduced migraine attack frequency and migraine duration. Showed non-significant trend toward reduced pain severity.
How They Measured It
Migraine frequency, duration, pain severity
To assess evidence for feverfew in preventing migraine
Study Type
Cochrane systematic review
Purpose
To assess evidence for feverfew in preventing migraine
Dose
Various feverfew doses and preparations
Participants
561 patients with migraine history
Duration
Various
Results
One larger, rigorous study showed feverfew reduced migraine frequency by 0.6 per month compared to placebo. However, no effect on pain severity or duration.
How They Measured It
Meta-analysis of 6 RCTs on migraine frequency
To evaluate combination treatment of riboflavin, magnesium, and feverfew for migraine prophylaxis
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To evaluate combination treatment of riboflavin, magnesium, and feverfew for migraine prophylaxis
Dose
2.65 mg feverfew in combination
Participants
55 patients with frequent migraines
Duration
3 months
Results
Combination including feverfew showed significant reduction in migraine frequency compared to placebo.
How They Measured It
Migraine frequency and severity
Anti-Inflammatory & Pain Relief
To evaluate the safety and efficacy of 6.25 mg feverfew CO2-extract (MIG-99) in migraine prevention
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To evaluate the safety and efficacy of 6.25 mg feverfew CO2-extract (MIG-99) in migraine prevention
Dose
MIG-99 6.25 mg t.i.d.
Participants
Adult migraine patients
Duration
12 weeks
Results
Although some improvement noted, MIG-99 6.25 mg t.i.d. failed to show significant migraine prophylactic effect compared to placebo in this particular study.
How They Measured It
Migraine frequency, pain intensity
To evaluate the efficacy and safety of standardized Tanacetum parthenium for migraine prophylaxis with dose-response analysis
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To evaluate the efficacy and safety of standardized Tanacetum parthenium for migraine prophylaxis with dose-response analysis
Dose
0.3 mg, 1 mg, and 2.7 mg parthenolide (active component)
Participants
245 patients with migraine history
Duration
12 weeks
Results
Dose-response analysis of feverfew showed efficacy for migraine prevention with optimal effects at higher standardized doses.
How They Measured It
Migraine frequency, severity, associated symptoms
Frequently Asked Questions
Common questions about Feverfew research
There are currently 10 peer-reviewed studies on Feverfew (Tanacetum parthenium), involving 899 total participants. Research covers Migraine prevention, Anti-inflammatory, Pain relief. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (5 human studies), and reported outcomes.
Feverfew has been researched for: Migraine prevention, Anti-inflammatory, Pain relief. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 5 out of 10 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
